Cetrorelix studies: 83 papers with results
Page 2 of 2
Cetrorelix has 523 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
- GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome.
Hebisha SA · Journal of obstetrics and gynaecology of India · 2017
Non-randomized trial · 7 results
- Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes.
Kerimoğlu OS · Archives of gynecology and obstetrics · 2013
Non-randomized trial · 3 results
- Addition of GnRH antagonist in cycles of poor responders undergoing IVF.
Akman MA · Human reproduction (Oxford, England) · 2000
Non-randomized trial · 3 results
- Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
Felberbaum RE · Human reproduction (Oxford, England) · 1998
Non-randomized trial · 7 results
- [Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix].
Felberbaum RE · Contraception, fertilite, sexualite (1992) · 1999
Non-randomized trial · 7 results
- Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.
Verschraegen CF · Gynecologic oncology · 2003
Non-randomized trial · 10 results
- Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
Behre HM · Clinical endocrinology · 1994
Non-randomized trial · 11 results
- High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
Behre HM · The Journal of clinical endocrinology and metabolism · 1997
Non-randomized trial · 3 results
- High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome.
Bonilla-Musoles FM · Clinical and experimental obstetrics & gynecology · 2009
Non-randomized trial · 5 results
- A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
Leroy I · Fertility and sterility · 1994
Non-randomized trial · 14 results
- Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.
Büchter D · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 1999
Non-randomized trial · 6 results
- Hormonal responses to the new potent GnRH antagonist Cetrorelix.
Klingmüller D · Acta endocrinologica · 1993
Non-randomized trial · 11 results
- Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
Nagaraja NV · Clinical pharmacology and therapeutics · 2000
Non-randomized trial · 7 results
- Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
Ozelci R · Taiwanese journal of obstetrics & gynecology · 2019
Non-randomized trial · 4 results
- Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose.
Ponzano A · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2017
Non-randomized trial · 1 result
- [Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature].
Kably Ambe A · Ginecologia y obstetricia de Mexico · 2002
Non-randomized trial · 7 results
- Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix.
Ludwig M · Fertility and sterility · 2001
Observational study · 7 results
- Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
Broqua P · The Journal of pharmacology and experimental therapeutics · 2002
Animal study (in vivo) · 22 results
- The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice.
Meirow D · Human reproduction (Oxford, England) · 2004
Animal study (in vivo) · mouse · 3 results
- Effects of Phoenixin-14 on anxiolytic-like behavior in mice.
Jiang JH · Behavioural brain research · 2015
Animal study (in vivo) · mouse · 1 result
- Enhancement of A spermatogonial proliferation and differentiation in irradiated rats by gonadotropin-releasing hormone antagonist administration.
Shuttlesworth GA · Endocrinology · 2000
Animal study (in vivo) · rat · 7 results
- Impact of proestrous milieu on expression of orexin receptors and prepro-orexin in rat hypothalamus and hypophysis: actions of Cetrorelix and Nembutal.
Silveyra P · American journal of physiology. Endocrinology and metabolism · 2007
Animal study (in vivo) · rat · 6 results
- Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A · European journal of cancer (Oxford, England : 1990) · 1997
Animal study (in vivo) · mouse · 6 results
- Gonadotropin-releasing hormone analogs stimulate and testosterone inhibits the recovery of spermatogenesis in irradiated rats.
Shetty G · Endocrinology · 2000
Animal study (in vivo) · rat · 9 results
- LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
Rick FG · The Prostate · 2011
Animal study (in vivo) · rat · 4 results
- Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Halmos G · Proceedings of the National Academy of Sciences of the United States of America · 1996
Animal study (in vivo) · rat · 7 results
- Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists.
Danforth DR · Fertility and sterility · 2005
Animal study (in vivo) · mouse · 2 results
- Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
Lin Y · Human reproduction (Oxford, England) · 1999
Ex vivo tissue · 1 result
- High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
Emons G · The Journal of clinical endocrinology and metabolism · 1993
In vitro (cells) · 2 results
- Modulation of human cytotrophoblastic leptin secretion by interleukin-1alpha and 17beta-oestradiol and its effect on HCG secretion.
Chardonnens D · Molecular human reproduction · 1999
In vitro (cells) · 1 result
- Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
Gründker C · European journal of endocrinology · 2004
In vitro (cells) · 1 result
- Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C · Gynecologic oncology · 2000
In vitro (cells) · 4 results
- Both orexin receptors are expressed in rat ovaries and fluctuate with the estrous cycle: effects of orexin receptor antagonists on gonadotropins and ovulation.
Silveyra P · American journal of physiology. Endocrinology and metabolism · 2007
Not a test of Cetrorelix alone · 3 results